REDLAMP 2: Disease Characteristics, Treatment Patterns, Prognosis, Outcomes, and Lymphoma-Related Mortality in Elderly Follicular Lymphoma

In a recent publication from the British Journal of Haematology researchers sought to better understand how patients over the age of 80 should be treated when they are diagnosed with follicular lymphoma. Dr. John Leonard discusses the implications of several of this study’s findings. Researchers found that while elderly follicular lymphoma patients were treated less aggressively, the majority of patients lived through the course of the study, with only a minority of those who died, dying from follicular lymphoma.

You can follow Lymphoma Program Director John Leonard @JohnPLeonardMD.

The previous entry can be viewed here.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 646-962-2074.

AACR 2015: Lymphoma Abstract Highlights

The annual American Association of Cancer Research (AACR) concluded last Wednesday in Philadelphia. Lymphoma related abstracts from researchers at the Meyer Cancer Center at Weill Cornell Medical College, presented results that could lead to potential new lymphoma therapies. These included:

Longitudinal genomic and transcriptomic analysis of mantle cell lymphoma in a targeted combination trial of a selective CDK4/6 inhibitor

In this study researchers from the Meyer Cancer Center used whole exome sequencing (WES) and whole transciptome sequencing (WTS) to study the progression of mantle cell lymphoma in patients, who had previously taken part in a clinical trial testing the combination of palbociclib and bortezomib. The primary goal was to understand the difference in response caused by genetic differentiations in those patients who responded to treatment and patients who did not respond to treatment. Investigators sought to understand these genetic differentiations by identifying copy number variants, single nucleotide variants, and differentially expressed genes. In doing so they were able to identify molecular clues to the mechanisms of resistance presented in patients with mantle cell lymphoma. These results are being followed up with in functional studies. They could potentially offer greater insight into the treatment of patients with mantle cell lymphoma.

Transcriptome sequencing of the Reed-Sternberg cells of classical Hodgkin lymphoma

Genomic studies of classical Hodgkin lymphoma (cHL) have been confined to cell lines due to the technological difficulties in isolating Hodgkin and Reed-Sternberg cells from reactive background tissue. However, a multi-disciplinary research team found a solution to the issues involved in isolating these cells. A flow cytometric cell isolation method allowed for the isolation of thousands of viable HRS cells from cHL tumors, which enabled the isolation of high quality RNA from HRS cells and intra-tumor B cells from 9 primary cases of cHL.  The team also sequenced the transcriptomes of four cell lines, and conducted a search for activated pathways. In the future, this form of analysis of HRS cells will allow for the expanded study of cHL pathogenesis. This line of analysis could potentially lead to new individualized approaches to therapy through the identification of altered signaling pathways.

REDLAMP – Review of Emerging Data for Lymphoma Patients – “Video Journal Club” Launched by Weill Cornell Lymphoma Program

Red Lamp logoThe Lymphoma Program at Weill Cornell Medical College, Meyer Cancer Center, and NewYork-Presbyterian is pleased to announce the initiation of a novel program to better inform patients and families dealing with lymphoma, chronic lymphocytic leukemia, and related disorders.

We will be presenting regular (roughly weekly) video programs where faculty briefly (3-5 minutes) review a new research publication that is important for lymphoma patients to learn about in terms that are understandable and relevant. The topics will be selected by our expert lymphoma faculty based on their importance to the field and our desire to make sure that lymphoma patients learn about new developments in a timely fashion.

The program will be named “REDLAMP” – Review of Emerging Data for Lymphoma Patients. Beyond the acronym, RED is also a nod to the colors of Weill Cornell Medical College, Cornell University and NewYork-Presbyterian (and blood cancers in general), while “LAMP” references our desire to “shine light” on important information for patients.

Our first video can be found below:

You can follow Lymphoma Program Director John Leonard @JohnPLeonardMD.

We encourage you to follow us on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 646-962-2074.